부산대학교 도서관

Despite the increasing adoption of insulin pumps and continuous glucose monitoring devices, most people with type 1 diabetes do not achieve their glycemic goals.sup.1. This could be related to a lack of expertise or inadequate time for clinicians to analyze complex sensor-augmented pump data. We tested whether frequent insulin dose adjustments guided by an automated artificial intelligence-based decision support system (AI-DSS) is as effective and safe as those guided by physicians in controlling glucose levels. ADVICE4U was a six-month, multicenter, multinational, parallel, randomized controlled, non-inferiority trial in 108 participants with type 1 diabetes, aged 10-21 years and using insulin pump therapy (ClinicalTrials.gov no. NCT03003806). Participants were randomized 1:1 to receive remote insulin dose adjustment every three weeks guided by either an AI-DSS, (AI-DSS arm, n = 54) or by physicians (physician arm, n = 54). The results for the primary efficacy measure--the percentage of time spent within the target glucose range (70-180 mg dl.sup.-1 (3.9-10.0 mmol l.sup.-1))--in the AI-DSS arm were statistically non-inferior to those in the physician arm (50.2 [plus or minus] 11.1% versus 51.6 [plus or minus] 11.3%, respectively, P < 1 × 10.sup.-7). The percentage of readings below 54 mg dl.sup.-1 ( The randomized-controlled trial ADVICE4U demonstrates non-inferiority of an automated AI-based decision support system compared with advice from expert physicians for optimal insulin dosing in youths with type 1 diabetes.
Author(s): Revital Nimri [sup.1] , Tadej Battelino [sup.2] , Lori M. Laffel [sup.3] , Robert H. Slover [sup.4] , Desmond Schatz [sup.5] , Stuart A. Weinzimer [sup.6] , Klemen Dovc [...]